Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer

G. Pizzocaro, L. Piva, M. Faustini, E. Spino, A. Milani

Research output: Contribution to journalArticle

Abstract

From September 1984 to December 1988, 28 consecutive patients with metastatic urothelial cancer entered a randomized study to compare 4 courses of modified methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) to 4 courses of methotrexate followed by folinic acid rescue and cisplatin (MP). Non-responders or relapsing patients were to be crossed to the other therapy. Hematological toxicity was more frequent (85%), but less severe, in patients treated with M-VAC than in patients treated with MP (21%, with 1 septic death) . Complete plus partial remissions were achieved in 10 (71.4%) of 14 patients treated with M-VAC and in 6 (50%) of the 12 evaluable patients treated with MP. The 20% difference lay only on complete remissions, which were 8.3% in the MP versus 28.5% in the M-VAC group. At cross-over, however, only 1 of 5 patients resistant to MP responded to M-VAC, while 3 of 5 patients resistant to M-VAC responded to MP. It seems that M-VAC should be considered as the first-line thrapy of choice in metastatic urothelial cancer, while MP, or high-dose methotrexate, could be considered for salvage.

Original languageEnglish
Pages (from-to)89-92
Number of pages4
JournalEuropean Urology
Volume20
Issue number2
Publication statusPublished - 1991

Fingerprint

Vinblastine
Methotrexate
Doxorubicin
Cisplatin
Neoplasms
Leucovorin

Keywords

  • Chemotherapy
  • Metastatic urothelial cancer
  • Response
  • Toxicity

ASJC Scopus subject areas

  • Urology

Cite this

Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. / Pizzocaro, G.; Piva, L.; Faustini, M.; Spino, E.; Milani, A.

In: European Urology, Vol. 20, No. 2, 1991, p. 89-92.

Research output: Contribution to journalArticle

Pizzocaro, G. ; Piva, L. ; Faustini, M. ; Spino, E. ; Milani, A. / Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. In: European Urology. 1991 ; Vol. 20, No. 2. pp. 89-92.
@article{a297104be0ed45eea876cd07f5a81cc0,
title = "Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer",
abstract = "From September 1984 to December 1988, 28 consecutive patients with metastatic urothelial cancer entered a randomized study to compare 4 courses of modified methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) to 4 courses of methotrexate followed by folinic acid rescue and cisplatin (MP). Non-responders or relapsing patients were to be crossed to the other therapy. Hematological toxicity was more frequent (85{\%}), but less severe, in patients treated with M-VAC than in patients treated with MP (21{\%}, with 1 septic death) . Complete plus partial remissions were achieved in 10 (71.4{\%}) of 14 patients treated with M-VAC and in 6 (50{\%}) of the 12 evaluable patients treated with MP. The 20{\%} difference lay only on complete remissions, which were 8.3{\%} in the MP versus 28.5{\%} in the M-VAC group. At cross-over, however, only 1 of 5 patients resistant to MP responded to M-VAC, while 3 of 5 patients resistant to M-VAC responded to MP. It seems that M-VAC should be considered as the first-line thrapy of choice in metastatic urothelial cancer, while MP, or high-dose methotrexate, could be considered for salvage.",
keywords = "Chemotherapy, Metastatic urothelial cancer, Response, Toxicity",
author = "G. Pizzocaro and L. Piva and M. Faustini and E. Spino and A. Milani",
year = "1991",
language = "English",
volume = "20",
pages = "89--92",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer

AU - Pizzocaro, G.

AU - Piva, L.

AU - Faustini, M.

AU - Spino, E.

AU - Milani, A.

PY - 1991

Y1 - 1991

N2 - From September 1984 to December 1988, 28 consecutive patients with metastatic urothelial cancer entered a randomized study to compare 4 courses of modified methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) to 4 courses of methotrexate followed by folinic acid rescue and cisplatin (MP). Non-responders or relapsing patients were to be crossed to the other therapy. Hematological toxicity was more frequent (85%), but less severe, in patients treated with M-VAC than in patients treated with MP (21%, with 1 septic death) . Complete plus partial remissions were achieved in 10 (71.4%) of 14 patients treated with M-VAC and in 6 (50%) of the 12 evaluable patients treated with MP. The 20% difference lay only on complete remissions, which were 8.3% in the MP versus 28.5% in the M-VAC group. At cross-over, however, only 1 of 5 patients resistant to MP responded to M-VAC, while 3 of 5 patients resistant to M-VAC responded to MP. It seems that M-VAC should be considered as the first-line thrapy of choice in metastatic urothelial cancer, while MP, or high-dose methotrexate, could be considered for salvage.

AB - From September 1984 to December 1988, 28 consecutive patients with metastatic urothelial cancer entered a randomized study to compare 4 courses of modified methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) to 4 courses of methotrexate followed by folinic acid rescue and cisplatin (MP). Non-responders or relapsing patients were to be crossed to the other therapy. Hematological toxicity was more frequent (85%), but less severe, in patients treated with M-VAC than in patients treated with MP (21%, with 1 septic death) . Complete plus partial remissions were achieved in 10 (71.4%) of 14 patients treated with M-VAC and in 6 (50%) of the 12 evaluable patients treated with MP. The 20% difference lay only on complete remissions, which were 8.3% in the MP versus 28.5% in the M-VAC group. At cross-over, however, only 1 of 5 patients resistant to MP responded to M-VAC, while 3 of 5 patients resistant to M-VAC responded to MP. It seems that M-VAC should be considered as the first-line thrapy of choice in metastatic urothelial cancer, while MP, or high-dose methotrexate, could be considered for salvage.

KW - Chemotherapy

KW - Metastatic urothelial cancer

KW - Response

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0026054168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026054168&partnerID=8YFLogxK

M3 - Article

C2 - 1752280

AN - SCOPUS:0026054168

VL - 20

SP - 89

EP - 92

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 2

ER -